Deploys Capital into Cash-Flowing Manufacturing Businesses in Aerospace, Defense and IT Packaging Advances Dual Myostatin Assets Targeting Muscle Preservation in Potential Combination with GLP-1 TreatmentsNEWPORT BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) — PMGC Holdings Inc. (NASDAQ: ELAB) (“the Company,” “PMGC,” “we,” or “our”) today filed its Annual Report on Form 10-K (“Annual Report”) for the fiscal year ended December 31, 2025 (“FYE 2025”), with the U.S. Securities and Exchange Commission (“SEC”). The Annual Report is available on the SEC’s website at www.sec.gov under the Company’s filings and on the Company’s investor relations website. A Year of Capital Allocation and Asset Growth Fiscal 2025 marked a year of disciplined capital deployment and balance sheet expansion.Total assets increased 43%, from approximately...

New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies  KOASTAL-2 and -3 fully enrolled in the first quarter of 2026; on track for topline readout in the second quarter of 2026 NMRA-898 selected as lead program in M4 franchise based on promising clinical results from ongoing Phase 1 study Strong financial position with $182.5 million in cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027 Company to host conference call today at 8:00 a.m. ET WATERTOWN, Mass., March 30, 2026 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved,...

DALIAN, China, March 30, 2026 (GLOBE NEWSWIRE) — CBAK Energy Technology, Inc. (NASDAQ: CBAT) (“CBAK Energy,” or the “Company”), a leading lithium-ion battery manufacturer and electric energy solution provider in China, today reported its unaudited financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial and Operational HighlightsFourth Quarter Consolidated Net Revenues achieved an explosive 131.8% year-over-year growth, reaching $58.80 million, compared to $25.37 million in the fourth quarter of 2024. This hyper-growth in the top line effectively decoupled from the temporary bottom-line pressures caused by ongoing capacity transitions. Fourth Quarter Net Revenues from Light Electric Vehicles (LEV) skyrocketed by 524.1% year-over-year to $12.92 million, compared...

– Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia – – Current data package highlights well-tolerated long-term safety profile, broad-spectrum clinical activity, and favorable adherence for once daily brilaroxazine up to one year – – Initiation of RECOVER-2 registrational trial planned in mid-2026 – CUPERTINO, Calif., March 30, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the full year ended December 31,...

Ci-joint le rapport financier annuel 2025AttachmentRapport Financier CRCAM 2025

HANGZHOU, China, March 30, 2026 (GLOBE NEWSWIRE) — On March 27, CaoCao Mobility (stock code: 02643.HK) released its 2025 annual results announcement. During the reporting period, the Company recorded revenue of RMB20.2 billion, representing a year-on-year increase of 37.7%. Gross margin rose by 1.3 percentage points to 9.4%, and net cash generated from operating activities increased by 60.3% year-on-year, indicating a notable enhancement in cash generation capability. The Company achieved positive adjusted net profit for the first time in the fourth quarter of 2025, marking a milestone breakthrough as it embarks on a path of profitable growth. The transformation to Robotaxi has been fully accelerated. Leveraging its three-in-one development strategy of “smart purpose-built vehicles + intelligent driving technology + intelligent...

Villers-lès-Nancy, 30 March 2026 – 08:00 (CEST) PRESS RELEASE          2025 annual resultsEquasens reports a solid performanceacross all financial indicatorsFY 2025 revenue of €236.5 million (+9.1%): continued strong performance driven by a portfolio of innovative solutions for healthcare professionals and providers Annual Recurring Revenue (ARR) up sharply: €108.0 million at December 31, 2025, representing 8.8% growth versus 2024EBITDA of €66.7 million (+9.1%), highlighting effective cost control in a sustained growth environmentCurrent operating income of €48.2 million (+6.8%), including the impact of investments in the new healthcare data infrastructureNet profit increased by 8.8% to €41.1 million, supporting the proposed distribution of a €1.40 gross dividend per share for FY 2025, subject to approval by the General...

EUROCASTLE INVESTMENT LIMITED                                       FOR IMMEDIATE RELEASEContact:        Oak Fund Services (Guernsey) LimitedCompany AdministratorAttn: Nicole BarnesTel: +44 1481 723450         Eurocastle Releases Fourth Quarter and Year End 2025 Financial Results Guernsey, 30 March 2026 – Eurocastle Investment Limited (Euronext Amsterdam: ECT) today has released its annual report for the year ended 31 December 2025.NAV of €20.60 million, or €20.51 per share, vs the Company’s previously reported Adjusted NAV of €15.01 per share as at Q3 2025 and €11.34 per share as at YE 2024, reflecting the release of all remaining Additional Reserves during 2025:During 2025, the Board determined that the reserves relating to the Realisation Plan were no longer required and these were released in full. This decision was taken in light...

FULL-YEAR 2025 RESULTS: SOLID GROWTH AND IMPROVED SECOND-HALF PROFITABILITY_____Net sales: €242.6m (+ 11.4%) Net revenue (gross margin): €180.5m (+ 6.8%) EBITDA1: €23.7m (+0.8%), with a strong improvement in the second half (+38.4% vs. first half) Net income (Group share): €9.6m, representing 5.3% of net revenue Proposed dividend: €0.76 per share Ambition 2030: scaling the model and accelerating international expansionParis, 30 March 2026 (8h00) – ADLPartner, the parent company of the DÉKUPLE Group, a European leader in communication and data marketing, is reporting its full-year 2025 results. Bertrand Laurioz, DÉKUPLE Group Chairman and CEO: “2025 marks a new milestone in the transformation and international expansion of the DÉKUPLE Group. In a mixed economic environment, the Group continued its growth trajectory, with net sales reaching...

Gross margin rises to 93.7%, EBITDA reaches €672K (15.53% margin), and the company moves to a pro forma net cash position Bilbao, March 30, 2026.- Virtualware (Euronext Growth Paris: ALVIR) closed 2025 with a gross margin of 93.7%, up from 86.8% in the prior year, and EBITDA of €672,626 (15.53% margin), according to audited annual results filed today with Euronext. The figures confirm the operational picture outlined in the February preliminary communication and show margin improvement, reflecting discipline and resilience throughout the year. Audited revenues reached €4.32 million, in line with the preliminary figure. The EBITDA improvement from the €598,500 (13.8%) reported in the unaudited release reflects the final allocation of depreciation and subsidy recognition under the audited close. The gross margin expansion was driven by the...